Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal

International Journal of Radiation Oncology Biology Physics

Volumn 45, Issue 2, 1999, Pages 309-314

  Wong, C Shun ^a   Tsao, Ming S ^b   Sharma, Vinay ^c   Chapman, William B ^b   Pintilie, Melania ^b   Cummings, Bernard J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

5 FU; Anal canal; Epidermoid carcinoma; Mitomycin C; p53; Radiotherapy

Indexed keywords

FLUOROURACIL; MITOMYCIN C; PROTEIN P53;

ADULT; AGED; ANUS CARCINOMA; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ENDOTHELIAL GROWTH FACTORS; FEMALE; FLUOROURACIL; HUMANS; LYMPHOKINES; MALE; MIDDLE AGED; MITOMYCIN; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032820443     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00188-1     Document Type: Article

References (31)

1. Nigro N.D., Vaitkevicius V.K., Considine B. Jr. Combined therapy for cancer of the anal canal A preliminary report . Dis Colon Rectum. 17:1974;354-356.
2. Cummings B.J., Keane T.J., O'Sullivan B., Wong C.S., Catton C.N. Epidermoid anal cancer Treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C . Int J Radiat Oncol Biol Phys. 21:1991;1115-1125.
3. Epidermoid anal cancer Results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research . Lancet. 348:1996;1049-1054.
4. Bartelink H., Roelofsen F., Eschwege F., Rougier P., Bosset J.F., Gonzalez D.G., Peiffert D., van Glabbeke M., Pierart M. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups . J Clin Oncol. 15:1997;2040-2049.
5. Flam M., John M., Pajak T.F., Petrelli N., Myerson R., Doggett S., Quivey J., Rotman M., Kerman H., Coia L., Murray K. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal Results of a phase III randomized intergroup study . J Clin Oncol. 14:1996;2527-2539.
6. Kastan M.B., Canman C.E., Leonard C.J. p53, cell cycle control and apoptosis Implications for cancer . Cancer Metastasis Rev. 14:1995;3-15.
7. Vogelstein B., Kinzler K.W. p53 function and dysfunction. Cell. 70:1992;523-526.
8. Chang F., Syrjanen S., Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol. 13:1995;1009-1022.
9. Rickert R.R. Disorders of the anal region. Ming S.C., Goldman H. Pathology of the gastrointestinal tract. 1992;882-903 W.B. Saunders, Toronto.
10. Williams G.R., Talbot I.C. Anal carcinoma - a histological review. Histopathology. 25:1994;507-516.
11. Tsao M.S., Liu N., Nicklee T., Shepherd F., Viallet J. Angiogensis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. J Clin Cancer Res. 3:1997;1807-1814.
12. Ogunbiyi O.A., Scholefield J.H., Smith J.H., Polacarz S.V., Rogers K., Sharp F. Immunohistochemical analysis of p53 expression in anal squamous neoplasia. J Clin Pathol. 46:1993;507-512.
13. Benchimol S., Lamb P., Crawford L.V., Sheer D., Shows T.B., Bruns G.A., Peacock J. Transformation associated p53 protein is encoded by a gene on human chromosome 17. Somat Cell Mol Genet. 11:1985;505-510.
14. Ahomadegbe J.C., Barrois M., Fogel S., Le Bihan M.L., Douc-Rasy S., Duvillard P., Armand J.P., Riou G. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene. 10:1995;1217-1227.
15. Baas I.O., Mulder J.W., Offerhaus G.J., Vogelstein B., Hamilton S.R. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol. 172:1994;5-12.
16. Jakate S.M., Saclarides T.J. Immunohistochemical detection of mutant p53 protein and human papillomavirus-related E6 protein in anal cancers. Dis Colon Rectum. 36:1993;1026-1029.
17. Tanum G., Holm R. Anal carcinoma A clinical approach to p53 and RB gene proteins . Oncology. 53:1996;369-373.
18. Crook T., Wrede D., Tidy J., Scholefield J., Crawford L., Vousden K.H. Status of c-myc, p53 and retinoblastoma genes in human papillomavirus positive and negative squamous cell carcinomas of the anus. Oncogene. 6:1991;1251-1257.
19. Coulter L.K., Wolber R., Tron V.A. Site-specific comparison of p53 immunostaining in squamous cell carcinomas. Hum Pathol. 26:1995;531-533.
20. Williams G.R., Lu Q.L., Love S.B., Talbot I.C., Northover J.M. Properties of HPV-positive and HPV-negative anal carcinomas. J Pathol. 180:1996;378-382.
21. Frisch M., Glimelius B., van den Brule A.J., Wohlfahrt J., Meijer C.J., Walboomers J.M., Goldman S., Svensson C., Adami H.O., Melbye M. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 337:1997;1350-1358.
22. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 75:1993;495-505.
23. Marston N.J., Crook T., Vousden K.H. Interaction of p53 with MDM2 is independent E6 and does not mediate wild type transformation suppressor function. Oncogene. 9:1994;2707-2716.
24. Medcalf E.A., Milner J. Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+ p53 conformation. Oncogene. 8:1993;2847-2851.
25. Hall P.A., Lane D.P. p53 in tumor pathology Can we trust immunohistochemistry? - Revisited! J Pathol. 172:1994;1-4.
26. Clarke A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper M.L., Wyllie A.H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 362:1993;849-852.
27. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:1993;847-849.
28. Bristow R.G., Benchimol S., Hill R.P. The p53 gene as a modifier of intrinsic radiosensitivity Implications for radiotherapy . Radiother Oncol. 40:1996;197-223.
29. Indinnimeo M., Cicchini C., Stazi A., Limiti M.R., Giarnieri E., Ghini C., Vecchione A. The prevalence of p53 immunoreactivity in anal canal carcinoma. Oncol Rep. 5:1998;1455-1457.
30. Tanum G., Tveit K., Karlsen K.O., Hauer-Jensen M. Chemotherapy and radiation therapy for anal carcinoma Survival and late morbidity . Cancer. 67:1991;2462-2466.
31. Bonin S.R., Pajak T.F., Russell A.H., Coia L.R., Paris K.J., Flam M.S., Santer E.R. Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal A report of Radiation Therapy Oncology Group randomized trial 87-04 . Cancer. 85:1999;1226-1233.